Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)

Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J. Martin, Martin R. Stockler, Anthony M. Joshua and Louise Emmett
Journal of Nuclear Medicine January 2023, 64 (1) 69-74; DOI: https://doi.org/10.2967/jnumed.122.264104
Sarennya Pathmanandavel
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
2Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
3Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan Crumbaker
2Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
3Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
4St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Nguyen
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
4St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew O. Yam
2Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
3Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
4St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Wilson
5MIM Software, Inc., Cleveland, Ohio;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Remy Niman
5MIM Software, Inc., Cleveland, Ohio;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Ayers
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shikha Sharma
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Eu
6Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J. Martin
7NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin R. Stockler
7NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony M. Joshua
2Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
3Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
4St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
8Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise Emmett
1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
3Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
4St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
8Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 64 no. 1 69-74
DOI 
https://doi.org/10.2967/jnumed.122.264104
PubMed 
35738906

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication March 5, 2022
  • Revision received June 13, 2022
  • Published online January 4, 2023.

Article Versions

  • previous version (June 23, 2022 - 10:30).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Sarennya Pathmanandavel1,2,3,
  2. Megan Crumbaker2,3,4,
  3. Andrew Nguyen1,4,
  4. Andrew O. Yam2,3,4,
  5. Peter Wilson5,
  6. Remy Niman5,
  7. Maria Ayers1,
  8. Shikha Sharma1,
  9. Peter Eu6,
  10. Andrew J. Martin7,
  11. Martin R. Stockler7,
  12. Anthony M. Joshua2,3,4,8 and
  13. Louise Emmett1,3,4,8
  1. 1Department of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
  2. 2Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, New South Wales, Australia;
  3. 3Garvan Institute of Medical Research, Sydney, New South Wales, Australia;
  4. 4St. Vincent’s Clinical School, University of New South Wales, Sydney, New South Wales, Australia;
  5. 5MIM Software, Inc., Cleveland, Ohio;
  6. 6Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
  7. 7NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia; and
  8. 8Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
  1. For correspondence or reprints, contact Sarennya Pathmanandavel (sarennya{at}gmail.com).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 18 Citations
  • 17 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Using PSMA imaging for prognostication in localized and advanced prostate cancer
    Matthew J. Roberts, Tobias Maurer, Marlon Perera, Matthias Eiber, Thomas A. Hope, Piet Ost, Shankar Siva, Michael S. Hofman, Declan G. Murphy, Louise Emmett, Wolfgang P. Fendler
    Nature Reviews Urology 2023 20 1
  • PSMA PET imaging in the diagnosis and management of prostate cancer
    Sina Houshmand, Courtney Lawhn-Heath, Spencer Behr
    Abdominal Radiology 2023 48 12
  • Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)
    Louise Emmett, Nikeith John, Sarennya Pathmanandavel, William Counter, Maria Ayers, Shikha Sharma, Shikha Agrawal, Aron Poole, Elizabeth Hovey, Ganes Pranavan, Craig Gedye, Girish Mallesara, Alex Guminski, Adrian Lee, Martin R. Stockler, Adam Hickey, Peter Eu, Anthony M. Joshua, Megan Crumbaker, Andrew Nguyen
    Therapeutic Advances in Medical Oncology 2023 15
  • Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
    Vishnu Murthy, Andrei Gafita, Pan Thin, Kathleen Nguyen, Tristan Grogan, John Shen, Alexandra Drakaki, Matthew Rettig, Johannes Czernin, Jeremie Calais
    Journal of Nuclear Medicine 2023 64 11
  • Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
    Megan Crumbaker, Leonard D. Goldstein, David H. Murray, Jiang Tao, Sarennya Pathmanandavel, Nicky Boulter, Lalith Ratnayake, Anthony M. Joshua, Sarah Kummerfeld, Louise Emmett
    European Urology Open Science 2023 57
  • Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives
    Fabio Volpe, Carmela Nappi, Leandra Piscopo, Emilia Zampella, Ciro Gabriele Mainolfi, Andrea Ponsiglione, Massimo Imbriaco, Alberto Cuocolo, Michele Klain
    Cancers 2023 15 19
  • How to Report PSMA PET
    Mina Swiha, Narjess Ayati, Daniela E. Oprea-Lager, Francesco Ceci, Louise Emmett
    Seminars in Nuclear Medicine 2024 54 1
  • Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics
    Nathan Kauffman, James Morrison, Kevin O’Brien, Jinda Fan, Kurt R. Zinn
    Pharmaceutics 2023 15 4
  • Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT
    Florian Rosar, Caroline Burgard, Scott David, Robert J. Marlowe, Mark Bartholomä, Stephan Maus, Sven Petto, Fadi Khreish, Andrea Schaefer-Schuler, Samer Ezziddin
    Scientific Reports 2024 14 1
  • Future Imaging of Prostate Cancer: Do We Need More Than PSMA PET/CT?
    Luigia Vetrone, Emilia Fortunati, Paolo Castellucci, Stefano Fanti
    Seminars in Nuclear Medicine 2024 54 1

Article usage

Article usage: June 2022 to April 2025

AbstractFullPdf
Jun 20221165033
Jul 20221329045
Aug 2022419010
Sep 2022382011
Oct 2022253010
Nov 2022210014
Dec 202213406
Jan 202312664777
Feb 20237871945
Mar 20236802740
Apr 20234322125
May 20233651428
Jun 20233381124
Jul 20235523444
Aug 20235235769
Sep 20235228651
Oct 20234814345
Nov 20235212037
Dec 2023508242
Jan 20245418239
Feb 20245218535
Mar 20244112172
Apr 2024576651
May 2024288337
Jun 2024479249
Jul 20249713148
Aug 20248811163
Sep 2024175456
Oct 2024155539
Nov 2024335642
Dec 2024164347
Jan 2025263427
Feb 2025378946
Mar 2025147248
Apr 20251811466
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (1)
Journal of Nuclear Medicine
Vol. 64, Issue 1
January 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J. Martin, Martin R. Stockler, Anthony M. Joshua, Louise Emmett
Journal of Nuclear Medicine Jan 2023, 64 (1) 69-74; DOI: 10.2967/jnumed.122.264104

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O. Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J. Martin, Martin R. Stockler, Anthony M. Joshua, Louise Emmett
Journal of Nuclear Medicine Jan 2023, 64 (1) 69-74; DOI: 10.2967/jnumed.122.264104
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
  • Google Scholar

More in this TOC Section

  • Establishing In Vitro Dosimetric Models and Dose–Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors
  • Designed Ankyrin Repeat Protein–Mediated Peptide Nucleic Acid–Based Pretargeting: A Proof-of-Principle Study
  • [11C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B
Show more Basic Science Investigation

Similar Articles

Keywords

  • metastatic prostate cancer
  • theranostics
  • lutetium-PSMA
  • prognosis
  • therapy response
SNMMI

© 2025 SNMMI

Powered by HighWire